Cisplatin-based chemotherapy is associated with electrolyte abnormalities, nephrotoxicity with reduction of glomerular filtration and other adverse side effects. Cisplatin renal toxicity induces interstitial fibrosis and tubular dysfunction which causes Hypomagnesemia. Increase of number of chemotherapeutical cycles is followed by progressive decline of the extra — and intracellular magnesium (Mg) in patients with malignant tumours treated by chemotherapy.
Hypomagnesemia during and following PVB combination chemotherapy in patients with testicular cancer has been described. The aim of this study was found optimal scheme of Mg supplementation to prevent hypomagne-semia and to reduce treatment related morbidity and mortality.
The authors evaluated influence of sequence cisplatin containing infusion and MgS04 containing infusion in two groups of patients. They found in patients, who received at first cisplatin containing infusion (Groups I) pathologic levels of serum Mg following infusion. These levels were on lower limit of norm at the end of each cycle of chemotherapy. When infusion with MgS04 was given before cisplatin containing infusion (Group II) serum levels of Mg did not decline on pathologic levels during whole chemotherapy and aftsr finishing of each cycle they were significantly higher in comparison with first group of patients.
Hypomagnesemia in patients with germinal testicular tumors treated by chemotherapy with cisplatin
